Dynavax Technologies Corporation (NASDAQ:DVAX) announced topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, a shingles vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback